Zentalis Pharma downgraded by Wedbush with a new price target
$ZNTL
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush downgraded Zentalis Pharma from Outperform to Neutral and set a new price target of $12.00 from $38.00 previously
Get the next $ZNTL alert in real time by email
Get the next $ZNTL alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ZNTL
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2024 | $4.00 | Underperform → Neutral | Wedbush |
| 6/20/2024 | $28.00 → $5.00 | Buy → Neutral | UBS |
| 6/18/2024 | $42.00 → $6.00 | Buy → Hold | Jefferies |
| 6/18/2024 | $38.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/18/2024 | $15.00 → $4.00 | Neutral → Underperform | Wedbush |
| 6/18/2024 | Overweight → Equal Weight | Wells Fargo | |
| 11/8/2023 | $38.00 → $12.00 | Outperform → Neutral | Wedbush |
| 11/7/2023 | $15.00 | Outperform → Market Perform | Leerink Partners |
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced four poster presentations at the 2025
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug conjugates (ADCs) demonstrating synergistic antitumor effects SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL
Zentalis Pharma upgraded by Wedbush with a new price target
Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00
Zentalis Pharma downgraded by UBS with a new price target
UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously
Zentalis Pharma downgraded by Jefferies with a new price target
Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously
Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
Director Skvarka Jan bought $103,446 worth of shares (60,000 units at $1.72), increasing direct ownership by 67% to 149,551 units (SEC Form 4)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
Director Walker Luke Nathaniel bought $24,966 worth of shares (14,200 units at $1.76), increasing direct ownership by 20% to 86,681 units (SEC Form 4)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
PAO and Interim PFO Vultaggio Vincent was granted 158,586 shares and sold $4,476 worth of shares (2,615 units at $1.71), increasing direct ownership by 461% to 189,826 units (SEC Form 4)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
Chief Scientific Officer Lackner Mark sold $24,591 worth of shares (14,368 units at $1.71) and was granted 335,907 shares, increasing direct ownership by 168% to 512,856 units (SEC Form 4)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
SEC Form S-3 filed by Zentalis Pharmaceuticals Inc.
S-3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
SEC Form 10-K filed by Zentalis Pharmaceuticals Inc.
10-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a restructuring of its business operations and research and development organ
Zentalis Pharmaceuticals Announces Key Management Appointments
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer. "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies," said Julie Eastland, Chief Executive Officer. "To support this goal, we are continuing to tune our leadership team and today announced the appointment of two talented leaders with a strong track record o
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Management to host conference call today at 8:00 am ET SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da
Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)